KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer

Antonio Jimeno, Wells A. Messersmith, Fred R. Hirsch, Wilbur A. Franklin, S Gail Eckhardt

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.

Original languageEnglish (US)
Pages (from-to)110-113
Number of pages4
JournalCancer Journal
Volume15
Issue number2
DOIs
StatePublished - Mar 1 2009

Fingerprint

Colorectal Neoplasms
Mutation
Epidermal Growth Factor Receptor
Pharmaceutical Preparations
Biomarkers
Monoclonal Antibodies
Economics
Genes
Neoplasms
panitumumab
Cetuximab
Therapeutics

Keywords

  • Biomarker
  • Colorectal cancer
  • EGFR
  • KRAS

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. / Jimeno, Antonio; Messersmith, Wells A.; Hirsch, Fred R.; Franklin, Wilbur A.; Eckhardt, S Gail.

In: Cancer Journal, Vol. 15, No. 2, 01.03.2009, p. 110-113.

Research output: Contribution to journalReview article

Jimeno, Antonio ; Messersmith, Wells A. ; Hirsch, Fred R. ; Franklin, Wilbur A. ; Eckhardt, S Gail. / KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. In: Cancer Journal. 2009 ; Vol. 15, No. 2. pp. 110-113.
@article{4cbb0860e41f4a1dba630dafbad05410,
title = "KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer",
abstract = "Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.",
keywords = "Biomarker, Colorectal cancer, EGFR, KRAS",
author = "Antonio Jimeno and Messersmith, {Wells A.} and Hirsch, {Fred R.} and Franklin, {Wilbur A.} and Eckhardt, {S Gail}",
year = "2009",
month = "3",
day = "1",
doi = "10.1097/PPO.0b013e31819e3202",
language = "English (US)",
volume = "15",
pages = "110--113",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer

AU - Jimeno, Antonio

AU - Messersmith, Wells A.

AU - Hirsch, Fred R.

AU - Franklin, Wilbur A.

AU - Eckhardt, S Gail

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.

AB - Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitumumab. This represents a paradigm-changing event and will have substantial impact on current and future anticancer drug development. These results add to the economic and ethical considerations involved in the development of novel targeted therapies and should increase our scrutiny of mechanisms of resistance and predictive biomarkers while in earlier developmental stages. In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer.

KW - Biomarker

KW - Colorectal cancer

KW - EGFR

KW - KRAS

UR - http://www.scopus.com/inward/record.url?scp=68049124818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049124818&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31819e3202

DO - 10.1097/PPO.0b013e31819e3202

M3 - Review article

C2 - 19390304

AN - SCOPUS:68049124818

VL - 15

SP - 110

EP - 113

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 2

ER -